NRx Pharmaceuticals to Present at Noble Capital Markets Conference, Highlighting Depression Treatment Advancements

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics Inc. announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. The presentation will cover significant developments in the company's depression treatment pipeline, including the upcoming launch of a low-dose D-Cycloserine product designed to enhance the effectiveness of Transcranial Magnetic Stimulation for depression.

The company's expanded clinical operations in Florida and collaborations with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD will also be discussed during the conference presentation. These initiatives represent important advancements in addressing mental health conditions that affect millions of Americans, particularly within the veteran community where suicide rates remain a critical concern.

NRx Pharmaceuticals focuses on developing therapeutics based on its NMDA platform for central nervous system disorders, specifically targeting suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100, a preservative-free intravenous ketamine that has received Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. This designation accelerates the development and review of drugs that treat serious conditions and fill unmet medical needs.

The company has also developed NRX-101, an oral D-cycloserine/lurasidone combination that has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. Recent regulatory progress includes the filing of an Abbreviated New Drug Application and initiation of a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. Additional information about the company's development programs can be found at https://www.nrxpharma.com.

The implications of these developments extend beyond the pharmaceutical industry to healthcare providers, patients, and mental health advocates. The combination of D-Cycloserine with Transcranial Magnetic Stimulation represents a novel approach that could potentially improve treatment outcomes for depression patients who have not responded adequately to conventional therapies. For veterans suffering from PTSD and suicidal depression, these advancements offer hope for more effective treatment options specifically tailored to their unique needs and experiences.

The company's participation in the Noble Capital Markets conference provides investors and industry stakeholders with insight into the progress of these important therapeutic developments. As mental health treatment continues to evolve, innovations like those being developed by NRx Pharmaceuticals could significantly impact how depression and related conditions are treated in clinical practice. The full press release detailing these announcements is available at https://ibn.fm/KRCWz, while comprehensive disclaimers and terms of use can be reviewed at http://IBN.fm/Disclaimer.